Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis

被引:35
作者
Brankovic, Marija [1 ,2 ]
Jovanovic, Igor [1 ]
Dukic, Marija [1 ]
Radonjic, Tijana [1 ]
Opric, Svetlana [1 ]
Klasnja, Slobodan [1 ]
Zdravkovic, Marija [1 ,2 ]
机构
[1] Univ Hosp Med Ctr Bezanijska Kosa, Dr Zorza Matea Bb, Belgrade 11000, Serbia
[2] Univ Belgrade, Fac Med, Belgrade 11000, Serbia
关键词
lipids; metabolism; NASH; NAFLD; liver; FATTY LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; IMPROVES HEPATIC STEATOSIS; UNFOLDED PROTEIN RESPONSE; LIFE-STYLE INTERVENTIONS; INSULIN-RESISTANCE; GUT MICROBIOTA; CELL-DEATH; CARDIOVASCULAR-DISEASE; TRIGLYCERIDE SYNTHESIS;
D O I
10.3390/ijms23095146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxicity can influence the accumulation of reactive oxygen species (ROS), so oxidative stress is also crucial for the progression of NASH. Moreover, NASH is in strong connection with metabolic disorders, and supporting evidence shows that insulin resistance (IR) is in a close relation to NAFLD, as it is involved in the progression to NASH and further progression to hepatic fibrosis. The major issue is that, at the moment, NASH treatment is based on lifestyle changes only due to the fact that no approved therapeutic options are available. The development of new therapeutic strategies should be conducted towards the potential NAFLD and NASH treatment by the modulation of IR but also by dietary antioxidants. As it seems, NASH is going to be the leading indication for liver transplantation as a consequence of increased disease prevalence and the lack of approved treatment; thus, an effective solution is needed as soon as possible.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] CD44 is a key player in non-alcoholic steatohepatitis
    Patouraux, Stephanie
    Rousseau, Deborah
    Bonnafous, Stephanie
    Lebeaupin, Cynthia
    Luci, Carmelo
    Canivet, Clemence M.
    Schneck, Anne-Sophie
    Bertola, Adeline
    Saint-Paul, Marie-Christine
    Iannelli, Antonio
    Gugenheim, Jean
    Anty, Rodolphe
    Tran, Albert
    Bailly-Maitre, Beatrice
    Gual, Philippe
    JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 328 - 338
  • [32] Pathophysiology of Non-Alcoholic Steatohepatitis and Basis for Treatment
    Pinzani, Massimo
    DIGESTIVE DISEASES, 2011, 29 (02) : 243 - 248
  • [33] Processes exacerbating apoptosis in non-alcoholic steatohepatitis
    Afonso, Marta B.
    Castro, Rui E.
    Rodrigues, Cecilia M. P.
    CLINICAL SCIENCE, 2019, 133 (22) : 2245 - 2264
  • [34] Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
    Lequoy, Marie
    Gigante, Elia
    Couty, Jean-Pierre
    Desbois-Mouthon, Christele
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (01)
  • [35] Non-alcoholic fatty liver disease and lipotoxicity
    Wasilewska, Natalia
    Lebensztejn, Dariusz Marek
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 7 (01) : 1 - 6
  • [36] Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
    Ratziu, Vlad
    Zelber-Sagi, Shira
    CLINICS IN LIVER DISEASE, 2009, 13 (04) : 667 - +
  • [37] Non-alcoholic Steatohepatitis (NASH) and alcoholic Steatohepatitis (ASH)
    Roeb, Elke
    DRUG RESEARCH, 2021, 71 : S16 - S18
  • [38] Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
    Takaki, Akinobu
    Kawai, Daisuke
    Yamamoto, Kazuhide
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05) : 7352 - 7379
  • [39] Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
    Losekann, Alexandre
    Weston, Antonio C.
    de Mattos, Angelo A.
    Tovo, Cristiane V.
    de Carli, Luis A.
    Espindola, Marilia B.
    Pioner, Sergio R.
    Coral, Gabriela P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (10): : 25552 - 25559
  • [40] Evolving therapies for non-alcoholic steatohepatitis
    Tilg, Herbert
    Moschen, Alexander R.
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (06) : 687 - 696